Concepedia

Arundathy N. Bartlett-Pandite

AN

Statistics

Publications

6

Citations

148

H-Index

6

Active since

1990

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Dana-Farber Cancer Institute

Research Triangle Park Foundation

Memorial Sloan Kettering Cancer Center

City of Hope

Arundathy N. Bartlett-Pandite is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pharmacology.

Publications per year

1990–2017

6

Publications

6

Inhibition of endothelium-dependent vasorelaxation by sickle erythrocytes

Morris Mosseri, Arundathy N. Bartlett-Pandite, K Wenc et al. · American Heart Journal · 1993 · 51 citations

Medicine, Hematology, Physiology +9

Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with <i>BRAF</i> V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).

David Planchard, Harry J.M. Groen, Tae Min Kim et al. · Journal of Clinical Oncology · 2015 · 31 citations

Medicine, Oncology, Pharmacology +16

Sickle erythrocytes inhibit human endothelial cell DNA synthesis

Robert S. Weinstein, MA Zhou, Arundathy N. Bartlett-Pandite et al. · Blood · 1990 · 26 citations · Full text

Medicine, Cell Biology, Hematology +8

Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1<sup>c259</sup>t in HLA-A2<sup>+</sup> patients with synovial sarcoma (NCT01343043).

Crystal L. Mackall, William D. Tap, John Glod et al. · Journal of Clinical Oncology · 2017 · 20 citations

Life Sciences, Immunology, Oncology +15

Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC).

Toby Johnson, Chun‐Fang Xu, Toni K. Choueiri et al. · Journal of Clinical Oncology · 2014 · 10 citations

Medicine, Oncology, Pharmacology +17

1–5 of 6